FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasilington,	D.C.	20040

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response.	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Palleiko Benjamin L (Last) (First) (Middle)						Salvista Pharmaceuticals, Inc. [KALV] 3. Date of Earliest Transaction (Month/Day/Year)									tionship of Reporting all applicable) Director Officer (give title below)		10% Ow Other (s below)		ner
C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E					12/	12/30/2020									CFO, CBO & Secretary				
(Street) CAMBRIDGE MA 02142						4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indiv ine) X	′				
(=14)	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye					on	2A. Deemed Execution Date,		3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amo Securit Benefic Owned		unt of 6. (ies Fo (D) Following (I)		n: Direct r Indirect sstr. 4)	7. Nature of Indirect Beneficial Ownership	
		Code	v	Amount	(A) or (D)			Price	Reported Transact (Instr. 3		tion(s)			(Instr. 4)					
Common Stock 12/30/202						20			М		358	A	\$6.7	4 32		2,858		D	
Common Stock 12/30/202									S ⁽¹⁾		358	D	D \$20.0413 ⁽²⁾ 32,500			,500		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	ution Date, th/Day/Year)	4. Transa Code (8)				6. Date Exerc Expiration D (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y O' Fe Di OI (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	e V	(A)	(D)	Date Exercis	cisable	Expiration Date	Title	Amour or Number of Shares						
Employee Stock Option (right to	\$6.74	12/30/2020			M			358	(3))	12/28/2026	Common	n 358		\$0.00	59,253		D	

Explanation of Responses:

- 1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$20.00 to \$20.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- 3. The option is fully vested.

Remarks:

/s/ Benjamin L. Palleiko 01/04/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.